John T Strony, Sunita Mengers, Lakshmanan Sivasundaram, Margaret Sinkler, Qian Wu, Chenya Zhao, Abdus Sattar, Michael J Salata, James E Voos, Michael R Karns
{"title":"静脉注射和口服酮咯酸的阿片类稀释止痛方案可减少关节镜半月板手术后阿片类药物的用量和疼痛程度：一项前瞻性随机对照试验。","authors":"John T Strony, Sunita Mengers, Lakshmanan Sivasundaram, Margaret Sinkler, Qian Wu, Chenya Zhao, Abdus Sattar, Michael J Salata, James E Voos, Michael R Karns","doi":"10.1016/j.arthro.2024.08.035","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The primary purpose was to compare ketorolac to oxycodone-acetaminophen with respect to pain and opioid consumption after arthroscopic meniscus surgery. The secondary purpose was to compare short-term functional outcomes between the two protocols.</p><p><strong>Methods: </strong>A power analysis demonstrated that 43 patients were required. In this randomized control trial, patients with meniscal pathology undergoing arthroscopic meniscus surgery were included. Group 1 received oxycodone-acetaminophen alone. Group 2 received one dose of intravenous ketorolac intraoperatively, oral ketorolac upon discharge, and \"rescue\" oxycodone-acetaminophen. Patients recorded the number of opioid tablets consumed and visual analog pain scale (VAS) scores three times per day for five days postoperatively. Opioids were converted to morphine milligram equivalents (MME). VAS, Lysholm Knee Scoring Scale (LKSS), and Knee Injury and Osteoarthritis Outcome Score (KOOS) were obtained.</p><p><strong>Results: </strong>Forty-eight patients were randomized. There were 25 patients in the control group and 23 patients in the ketorolac group. The mean age was 47.9 (±14.3) years. Fifty-two percent (n=25) of the population were female. Three patients (6.3%) underwent meniscal repair. During the first five days postoperatively, the mean VAS score (β= -13.2, SE=5.97, p=0.029) and the MME consumed were significantly lower (β=-4.7, SE=1.93, p=0.015) per time point in the ketorolac group relative to the control group. The control group had better LKSS (80.6 [SD 18.5] versus 65 [SD 21.5], p=0.016) and KOOS (74.1 [SD 16.7] versus 61.9 [SD 18.6], p=0.029) scores at 6 weeks. There were no significant differences in the rates of side effects.</p><p><strong>Conclusions: </strong>An opioid-sparing pain protocol of intravenous and oral ketorolac is associated with significant reductions in VAS scores and MME consumption in the first five days after arthroscopic meniscus surgery. There were significant differences in patient-reported outcomes at final follow-up, favoring the control group. There were no significant differences in adverse reactions and side effects.</p><p><strong>Level of evidence: </strong>Therapeutic Level II, prospective randomized-controlled trial.</p>","PeriodicalId":55459,"journal":{"name":"Arthroscopy-The Journal of Arthroscopic and Related Surgery","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An Opioid-Sparing Pain Protocol of Intravenous and Oral Ketorolac Reduces Opioid Consumption and Pain Levels after Arthroscopic Meniscus Surgery: A Prospective, Randomized Controlled Trial.\",\"authors\":\"John T Strony, Sunita Mengers, Lakshmanan Sivasundaram, Margaret Sinkler, Qian Wu, Chenya Zhao, Abdus Sattar, Michael J Salata, James E Voos, Michael R Karns\",\"doi\":\"10.1016/j.arthro.2024.08.035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The primary purpose was to compare ketorolac to oxycodone-acetaminophen with respect to pain and opioid consumption after arthroscopic meniscus surgery. The secondary purpose was to compare short-term functional outcomes between the two protocols.</p><p><strong>Methods: </strong>A power analysis demonstrated that 43 patients were required. In this randomized control trial, patients with meniscal pathology undergoing arthroscopic meniscus surgery were included. Group 1 received oxycodone-acetaminophen alone. Group 2 received one dose of intravenous ketorolac intraoperatively, oral ketorolac upon discharge, and \\\"rescue\\\" oxycodone-acetaminophen. Patients recorded the number of opioid tablets consumed and visual analog pain scale (VAS) scores three times per day for five days postoperatively. Opioids were converted to morphine milligram equivalents (MME). VAS, Lysholm Knee Scoring Scale (LKSS), and Knee Injury and Osteoarthritis Outcome Score (KOOS) were obtained.</p><p><strong>Results: </strong>Forty-eight patients were randomized. There were 25 patients in the control group and 23 patients in the ketorolac group. The mean age was 47.9 (±14.3) years. Fifty-two percent (n=25) of the population were female. Three patients (6.3%) underwent meniscal repair. During the first five days postoperatively, the mean VAS score (β= -13.2, SE=5.97, p=0.029) and the MME consumed were significantly lower (β=-4.7, SE=1.93, p=0.015) per time point in the ketorolac group relative to the control group. The control group had better LKSS (80.6 [SD 18.5] versus 65 [SD 21.5], p=0.016) and KOOS (74.1 [SD 16.7] versus 61.9 [SD 18.6], p=0.029) scores at 6 weeks. There were no significant differences in the rates of side effects.</p><p><strong>Conclusions: </strong>An opioid-sparing pain protocol of intravenous and oral ketorolac is associated with significant reductions in VAS scores and MME consumption in the first five days after arthroscopic meniscus surgery. There were significant differences in patient-reported outcomes at final follow-up, favoring the control group. There were no significant differences in adverse reactions and side effects.</p><p><strong>Level of evidence: </strong>Therapeutic Level II, prospective randomized-controlled trial.</p>\",\"PeriodicalId\":55459,\"journal\":{\"name\":\"Arthroscopy-The Journal of Arthroscopic and Related Surgery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arthroscopy-The Journal of Arthroscopic and Related Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.arthro.2024.08.035\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ORTHOPEDICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthroscopy-The Journal of Arthroscopic and Related Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.arthro.2024.08.035","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
An Opioid-Sparing Pain Protocol of Intravenous and Oral Ketorolac Reduces Opioid Consumption and Pain Levels after Arthroscopic Meniscus Surgery: A Prospective, Randomized Controlled Trial.
Background: The primary purpose was to compare ketorolac to oxycodone-acetaminophen with respect to pain and opioid consumption after arthroscopic meniscus surgery. The secondary purpose was to compare short-term functional outcomes between the two protocols.
Methods: A power analysis demonstrated that 43 patients were required. In this randomized control trial, patients with meniscal pathology undergoing arthroscopic meniscus surgery were included. Group 1 received oxycodone-acetaminophen alone. Group 2 received one dose of intravenous ketorolac intraoperatively, oral ketorolac upon discharge, and "rescue" oxycodone-acetaminophen. Patients recorded the number of opioid tablets consumed and visual analog pain scale (VAS) scores three times per day for five days postoperatively. Opioids were converted to morphine milligram equivalents (MME). VAS, Lysholm Knee Scoring Scale (LKSS), and Knee Injury and Osteoarthritis Outcome Score (KOOS) were obtained.
Results: Forty-eight patients were randomized. There were 25 patients in the control group and 23 patients in the ketorolac group. The mean age was 47.9 (±14.3) years. Fifty-two percent (n=25) of the population were female. Three patients (6.3%) underwent meniscal repair. During the first five days postoperatively, the mean VAS score (β= -13.2, SE=5.97, p=0.029) and the MME consumed were significantly lower (β=-4.7, SE=1.93, p=0.015) per time point in the ketorolac group relative to the control group. The control group had better LKSS (80.6 [SD 18.5] versus 65 [SD 21.5], p=0.016) and KOOS (74.1 [SD 16.7] versus 61.9 [SD 18.6], p=0.029) scores at 6 weeks. There were no significant differences in the rates of side effects.
Conclusions: An opioid-sparing pain protocol of intravenous and oral ketorolac is associated with significant reductions in VAS scores and MME consumption in the first five days after arthroscopic meniscus surgery. There were significant differences in patient-reported outcomes at final follow-up, favoring the control group. There were no significant differences in adverse reactions and side effects.
Level of evidence: Therapeutic Level II, prospective randomized-controlled trial.
期刊介绍：
Nowhere is minimally invasive surgery explained better than in Arthroscopy, the leading peer-reviewed journal in the field. Every issue enables you to put into perspective the usefulness of the various emerging arthroscopic techniques. The advantages and disadvantages of these methods -- along with their applications in various situations -- are discussed in relation to their efficiency, efficacy and cost benefit. As a special incentive, paid subscribers also receive access to the journal expanded website.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
